Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 124

Sort by

Sort Order Select

Journal Articles

Venetoclax Dose Escalation Rapidly Activates a BAFF/BCL-2 Survival Axis in Chronic Lymphocytic Leukemia

Blood blood.2024024341.

https://doi.org/10.1182/blood.2024024341

Published: 2024

Includes: Supplemental data

Journal Articles

Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions

Blood (2024) 144 (8): 867–872.

https://doi.org/10.1182/blood.2023023388

Published: 2024

Includes: Supplemental data

Journal Articles

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG

Blood (2023) 142 (23): 1960–1971.

https://doi.org/10.1182/blood.2023020301

Published: 2023

Includes: Supplemental data

Journal Articles

Depletion of the Mitochondrial E3 Ligase MARCH5 Induces Synthetic Lethality to BCL2 Inhibitor (Venetoclax) Therapy in Cell Lines Representative of Diverse Blood Cancers

Thomas E Lew, Mark Van Delft, Chris Riffkin, Georgiou Angela, Christine White, Yin Yuan, Jahja Michelle, Mary Ann Anderson, Rachel Thijssen, David C.S. Huang, Mark A Dawson, Andrew W. Roberts

Blood (2023) 142 (Supplement 1): 415.

https://doi.org/10.1182/blood-2023-184392

Published: 2023

Journal Articles

Venetoclax Has Potent Efficacy in NPM1 mutated AML with Acquired Resistance Associated with Either Perturbed Pro-Survival Signalling or NPM1 wild-Type Populations

Blood (2023) 142 (Supplement 1): 423.

https://doi.org/10.1182/blood-2023-185321

Published: 2023

Journal Articles

Direct, Potent, and TP53-Independent Activity of Sting Agonists Against Acute Myeloid Leukaemia Enhances Venetoclax Efficacy In Vivo

Yin Yuan, Sarah T Diepstraten, Fiona C. Brown, Veronique Litalien, Andreas Strasser, Gemma L Kelly, Andrew W. Roberts, Andrew H. Wei

Blood (2023) 142 (Supplement 1): 4163.

https://doi.org/10.1182/blood-2023-179698

Published: 2023

Journal Articles

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia

Blood (2023) 141 (6): 634–644.

https://doi.org/10.1182/blood.2022016090

Published: 2023

Includes: Supplemental data

Journal Articles

Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy

Blood (2022) 140 (20): 2127–2141.

https://doi.org/10.1182/blood.2022016040

Published: 2022

Includes: Supplemental data

Journal Articles

Shielding the Vulnerable: A Multicentre Australian Rollout of Evusheld to Patients with Chronic Lymphocytic Leukaemia (CLL-SHIELD)

Ashley Whitechurch, Rory Bennett, Shafqat Inam, Benjamin Hartog, Rebecca Blackwood, Shevon Fernando, Felanita Hutani, Hadley Bortz, Mitchel Lincoln, Dennis Carney, Andrew W Roberts, Mary Ann Anderson, Constantine S. Tam, John F. Seymour

Blood (2022) 140 (Supplement 1): 9911–9912.

https://doi.org/10.1182/blood-2022-165609

Published: 2022

Journal Articles

ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial

Blood (2022) 140 (Supplement 1): 3341–3343.

https://doi.org/10.1182/blood-2022-167837

Published: 2022

Journal Articles

High Response and Prolonged Treatment-Free Remission after a Short-Course of Modified Intensive Chemotherapy and Venetoclax in Elderly AML: An Updated Analysis of the Caveat Trial

Chong Chyn Chua, Sun Loo, John Reynolds, Ing S Tiong, Chun Yew Fong, Stephen B Ting, Shaun Fleming, Andrew W Roberts, Andrew H Wei

Blood (2022) 140 (Supplement 1): 1708–1710.

https://doi.org/10.1182/blood-2022-165021

Published: 2022

Journal Articles

Clonal hematopoiesis, myeloid disorders and BAX -mutated myelopoiesis in patients receiving venetoclax for CLL

Piers Blombery, Thomas E. Lew, Michael A. Dengler, Ella R. Thompson, Victor S. Lin, Xiangting Chen, Tamia Nguyen, Ashish Panigrahi, Sasanka M. Handunnetti, Dennis A. Carney, David A. Westerman, Constantine S. Tam, Jerry M. Adams, Andrew H. Wei, David C. S. Huang, John F. Seymour, Andrew W. Roberts, Mary Ann Anderson

Blood (2022) 139 (8): 1198–1207.

https://doi.org/10.1182/blood.2021012775

Published: 2022

Includes: Supplemental data

Journal Articles

Deep Profiling of Chronic Lymphocytic Leukaemia (CLL) and Healthy Immune Cells By Mass Cytometry Resolves Impacts of Venetoclax Pressure

Charis E Teh, Tania Tan, Marie Trussart, Mengxiao Luo, Rachel Thijssen, Andrew W Roberts, David C.S. Huang, Terence Speed, Mary Ann Anderson, Daniel Gray

Blood (2021) 138 (Supplement 1): 3710.

https://doi.org/10.1182/blood-2021-149938

Published: 2021

Journal Articles

Introduction to a review series on small-molecule targeted therapies for lymphoid malignancies

Andrew W. Roberts, Freda K. Stevenson

Blood (2021) 138 (13): 1089.

https://doi.org/10.1182/blood.2021012674

Published: 2021

Journal Articles

BCL2 and MCL1 inhibitors for hematologic malignancies

Andrew W. Roberts, Andrew H. Wei, David C. S. Huang

Blood (2021) 138 (13): 1120–1136.

https://doi.org/10.1182/blood.2020006785

Published: 2021

Journal Articles

Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy

Shuo Ma, John F. Seymour, Danielle M. Brander, Thomas J. Kipps, Michael Y. Choi, Mary Ann Anderson, Kathryn Humphrey, Abdullah Al Masud, John Pesko, Ruby Nandam, Ahmed Hamed Salem, Brenda Chyla, Jennifer Arzt, Amanda Jacobson, Su Young Kim, Andrew W. Roberts

Blood (2021) 138 (10): 836–846.

https://doi.org/10.1182/blood.2020009578

Published: 2021

Includes: Supplemental data

Journal Articles

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias

Blood (2021) 137 (20): 2721–2735.

https://doi.org/10.1182/blood.2020010167

Published: 2021

Includes: Supplemental data

Journal Articles

Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-136872

Published: 2020

Journal Articles

BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia

Piers Blombery, MBBS, Ella R Thompson, PhD BSc, Xiangting Chen, PhD, Tamia Nguyen, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, David Alan Westerman, MBBS, FRCPA, FRACP, John F. Seymour, Constantine S. Tam, MBBS, MD, Michael A Dengler, PhD, David C.S. Huang, MBBS MRCP PhD, Andrew Wei, MBBS,PhD, Andrew W Roberts, MBBS

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-137775

Published: 2020

Journal Articles

The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3 -ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3 -ITD Acute Myeloid Leukemia (ALLG AMLM16)

Natasha S Anstee, PhD, Giovanna Pomilio, Mark Levis, MD PhD, Sarah MacRaild, Michael Murray, PhD DSc, Tristan Rawling, PhD, Glen A Kennedy, MBBS FRACP FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Anthony Schwarer, MBBS, MD FRACP, FRCPA, Anoop Kumar Enjeti, MBBS,FRCPA, FRACP, PhD MD MRCP, James D'Rozario, MBBS, FRACP, FRCPA, Paula Marlton, MBBS FRACP FRCPA, Ian Bilmon, BMBS, FRACP, FRCPA, Adam Ivey, BSc, MSc, PhD, Doen Ming Ong, MBBS, Andrew W Roberts, MBBS, Andrew H Wei, MBBS, PhD

Blood (2020) 136 (Supplement 1): 16–18.

https://doi.org/10.1182/blood-2020-141711

Published: 2020

NARROW

Venetoclax Dose Escalation Rapidly Activates a BAFF/BCL-2 Survival Axis in Chronic Lymphocytic Leukemia

Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG

Depletion of the Mitochondrial E3 Ligase MARCH5 Induces Synthetic Lethality to BCL2 Inhibitor (Venetoclax) Therapy in Cell Lines Representative of Diverse Blood Cancers

Venetoclax Has Potent Efficacy in NPM1 mutated AML with Acquired Resistance Associated with Either Perturbed Pro-Survival Signalling or NPM1 wild-Type Populations

Direct, Potent, and TP53-Independent Activity of Sting Agonists Against Acute Myeloid Leukaemia Enhances Venetoclax Efficacy In Vivo

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia

Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy

Shielding the Vulnerable: A Multicentre Australian Rollout of Evusheld to Patients with Chronic Lymphocytic Leukaemia (CLL-SHIELD)

ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial

High Response and Prolonged Treatment-Free Remission after a Short-Course of Modified Intensive Chemotherapy and Venetoclax in Elderly AML: An Updated Analysis of the Caveat Trial

Clonal hematopoiesis, myeloid disorders and BAX -mutated myelopoiesis in patients receiving venetoclax for CLL

Deep Profiling of Chronic Lymphocytic Leukaemia (CLL) and Healthy Immune Cells By Mass Cytometry Resolves Impacts of Venetoclax Pressure

Introduction to a review series on small-molecule targeted therapies for lymphoid malignancies

BCL2 and MCL1 inhibitors for hematologic malignancies

Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias

Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia

BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia

The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3 -ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3 -ITD Acute Myeloid Leukemia (ALLG AMLM16)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only